INVESTORS

Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.

 

About Us

Press Releases

Read about the latest Hoth Therapeutics
technology, research, investor updates
and much more.

Aug 2, 2021
Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The...

Jul 13, 2021
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne

NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive...

Jun 28, 2021
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa...

View All

Our Purpose

Founded in 2017, Hoth Therapeutics, Inc. was formed as a global platform to commercialize innovative and proprietary therapeutics. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders.

Home Page Icons
  • SEC Filings
    View annual filings, quarterly filings and more
  • FAQ's
    Check out our frequently asked questions for more information
  • Events
    Upcoming and past investor related events and announcements
Investor Presentation

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Download

Subscribe
Keep up to date on Hoth Therapeutics News. Simply fill out your email below and you will be added to our email alerts.
* Required Fields
Our Pipeline
  • On-The-Go SARS-Cov-2
  • BioLexa Platform
  • Halovax-Vaxcelerate
  • HT-001
  • HT-002
  • HT-003
  • HT-004
  • HT-005 Z-PODS™
  • HT-006

Hoth Therapeutics’ research and development activities are focused on creating novel therapies where an unmet medical need exists.

Investor Contact

LR Advisors LLC

Email: investorrelations@hoththerapeutics.com

Phone: (678) 570-6791